What is it about?
MEN2 is a heterogeneous hereditable disease that includes different clinical forms (MEN2A, MEN2B, FMTC). In all cases, affected people develop tumors of the thyroid with high probability, along with other more or less severe symptoms. A gene called RET is involved in the onset of this genetic syndrome. Drugs that block RET are under development in order to treat MEN2. The article describes recent advances in this field.
Featured Image
Why is it important?
This paper reports on most recent results obtained with anti-RET drugs and anticipates the upcoming of new, second-generation drugs. It is an overview of newest advances in the field of MEN2 treatment.
Perspectives
I hope the article may help people who are interested, to find important information on new drugs coming to the pharmaceutical market for MEN2 therapies.
Luca Mologni
Universita degli Studi di Milano-Bicocca
Read the Original
This page is a summary of: Novel targeted therapeutics for MEN2, Endocrine Related Cancer, January 2018, Bioscientifica,
DOI: 10.1530/erc-17-0297.
You can read the full text:
Contributors
The following have contributed to this page
